Holen Sie sich die Stockscreener-App
15.90
3.23%
-0.53
Handel nachbörslich:
15.90
Schlusskurs vom Vortag:
$16.43
Offen:
$16.42
24-Stunden-Volumen:
342.82K
Relative Volume:
0.46
Marktkapitalisierung:
$458.92M
Einnahmen:
$66.59M
Nettoeinkommen (Verlust:
$-104.93M
KGV:
-3.2121
EPS:
-4.95
Netto-Cashflow:
$-96.48M
1W Leistung:
+1.21%
1M Leistung:
+12.61%
6M Leistung:
+112.00%
1J Leistung:
+171.79%
1-Tages-Spanne:
$15.80
$16.88
1-Wochen-Bereich:
$15.80
$17.15
52-Wochen-Spanne:
$4.09
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
15.90 | 474.21M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2025-10-01 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsTrend Following Strategies & Affordable Trading Portfolio - Bollywood Helpline
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains? - Yahoo Finance
What hedge fund activity signals for Enanta Pharmaceuticals Inc. stock2025 Market Outlook & Daily Growth Stock Investment Tips - Улправда
How Enanta Pharmaceuticals Inc. stock performs in interest rate cycles2025 Geopolitical Influence & Technical Pattern Recognition Alerts - Улправда
Does Enanta Pharmaceuticals Inc. stock trade at a discount to peersMarket Movement Recap & Smart Allocation Stock Tips - Улправда
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st
Rate Hike: Will Enanta Pharmaceuticals Inc. stock see insider buyingTrade Performance Summary & Daily Profit Focused Stock Screening - Улправда
Will Enanta Pharmaceuticals Inc. (9EP) stock see insider accumulationTrade Risk Report & Long-Term Safe Investment Ideas - Улправда
What margin trends mean for Enanta Pharmaceuticals Inc. stockJuly 2025 Retail & Free Verified High Yield Trade Plans - Улправда
Why Enanta Pharmaceuticals Inc. stock is considered a top pickMarket Activity Summary & Precise Trade Entry Recommendations - Улправда
Will Enanta Pharmaceuticals Inc. stock benefit from upcoming earnings reportsRate Hike & Accurate Technical Buy Alerts - Bölüm Sonu Canavarı
Aug Breakouts: Will Enanta Pharmaceuticals Inc. (9EP) stock outperform Dow Jones2025 Market Sentiment & Weekly High Momentum Picks - Улправда
Is Enanta Pharmaceuticals Inc. stock a buy in volatile marketsJuly 2025 Retail & Low Drawdown Momentum Ideas - DonanımHaber
Will Enanta Pharmaceuticals Inc. stock benefit from automation2025 Earnings Impact & AI Based Buy/Sell Signal Reports - DonanımHaber
Will Enanta Pharmaceuticals Inc. stock see insider buyingMarket Trend Report & Fast Exit and Entry Strategy Plans - Улправда
Why Enanta Pharmaceuticals Inc. stock appeals to analystsStop Loss & Expert Approved Trade Ideas - DonanımHaber
Is Enanta Pharmaceuticals Inc. stock trading at a premium valuation2025 Price Targets & Fast Entry Momentum Trade Alerts - Улправда
(ENTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Have Insiders Sold Enanta Pharmaceuticals Shares Recently? - simplywall.st
Enanta Pharmaceuticals falls on public offering of common stock - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Insider Scott Rottinghaus Sells 798 Shares - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) CEO Jay Luly Sells 4,743 Shares of Stock - MarketBeat
Enanta Pharma chief medical officer sells $11k in stock By Investing.com - Investing.com Canada
Tara Lynn Kieffer Sells 2,106 Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) Stock - MarketBeat
Enanta Pharma CBO Luu sells $19,836 in stock By Investing.com - Investing.com Canada
Enanta Pharma CBO Luu sells $19,836 in stock - Investing.com India
Enanta Pharma CSO Or Yat Sun sells $34k in stock - Investing.com India
Enanta Pharma CSO Or Yat Sun sells $34k in stock By Investing.com - Investing.com South Africa
Enanta Pharma chief product officer sells $30k in stock By Investing.com - Investing.com UK
Will Enanta Pharmaceuticals Inc. (9EP) stock extend growth storyJuly 2025 Intraday Action & Daily Profit Focused Screening - Newser
Can Enanta Pharmaceuticals Inc. (9EP) stock survive global slowdownJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Is Enanta Pharmaceuticals Inc. (9EP) stock nearing a technical breakout - Newser
Is Enanta Pharmaceuticals Inc. stock a top momentum playQuarterly Market Summary & Risk Controlled Daily Trade Plans - Newser
VP Or Surrenders 753 Of Enanta Pharmaceuticals Inc [ENTA] - TradingView
ENTA: RSV and immunology pipelines advance with key candidates and pivotal trials planned for 2026 - TradingView
Is Enanta Pharmaceuticals Inc. (9EP) stock a defensive play amid uncertainty - Newser
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Certain Options of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
Certain Common Stock of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
Portfolio Recap: What makes Enanta Pharmaceuticals Inc. stock attractive to growth funds2025 Winners & Losers & Risk Adjusted Swing Trade Ideas - moha.gov.vn
Enanta Pharmaceuticals Inc Stock Analysis and ForecastMarket Capitalization Trends & Free Unmatched Market Performance - earlytimes.in
Enanta Pharmaceuticals, Inc. (ENTA) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Enanta Pharmaceuticals insider awarded RSUs and 12,925 stock options - Stock Titan
[Form 4] ENANTA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):